Mitochondrial therapeutics in Alzheimer's disease and Parkinson's disease

被引:0
|
作者
Jake G Hoekstra
Kathleen S Montine
Jing Zhang
Thomas J Montine
机构
[1] University of Washington,Department of Pathology
关键词
Reactive Oxygen Species Production; Mitochondrial Dysfunction; Reactive Nitrogen Species; Mitochondrial Fission; Mitochondrial Dynamic;
D O I
暂无
中图分类号
学科分类号
摘要
In neurons, mitochondria serve a wide variety of processes that are integral to their function and survival. It is, therefore, not surprising that evidence of mitochondrial dysfunction is observed across numerous neurodegenerative diseases. Alzheimer's disease and Parkinson's disease are two such diseases in which aberrant mitochondrial activity is proposed to contribute to pathogenesis. Current therapies for each disease target various mechanisms, but few, if any, directly target improved mitochondrial function. Recent discoveries pertaining to mitochondrial dynamics reveal that regulation of mitochondrial fission and fusion may play a key role in the pathogenesis of these diseases and consequently could be novel future therapeutic targets.
引用
收藏
相关论文
共 50 条
  • [1] Mitochondrial therapeutics in Alzheimer's disease and Parkinson's disease
    Hoekstra, Jake G.
    Montine, Kathleen S.
    Zhang, Jing
    Montine, Thomas J.
    [J]. ALZHEIMERS RESEARCH & THERAPY, 2011, 3 (03):
  • [2] Novel Therapeutics for the Treatment of Alzheimer's and Parkinson's Disease
    Singh, Kavita
    Yadav, Dhananjay
    Chauhan, Pallavi S.
    Mishra, Meerambika
    Jin, Jun-O
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2020, 26 (07) : 755 - 763
  • [3] Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics
    Belaidi, Abdel A.
    Bush, Ashley I.
    [J]. JOURNAL OF NEUROCHEMISTRY, 2016, 139 : 179 - 197
  • [4] Mitochondrial mechanisms in Alzheimer?s disease: Quest for therapeutics
    Kalani, Komal
    Chaturvedi, Poonam
    Chaturvedi, Pankaj
    Verma, Vinod Kumar
    Lal, Nand
    Awasthi, Sudhir K.
    Kalani, Anuradha
    [J]. DRUG DISCOVERY TODAY, 2023, 28 (05)
  • [5] Are Parkinson's Disease Patients the Ideal Preclinical Population for Alzheimer's Disease Therapeutics?
    Tropea, Thomas F.
    Chen-Plotkin, Alice
    [J]. JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (09):
  • [6] Applications of Nanotechnology in Diagnostics and Therapeutics of Alzheimer's and Parkinson's Disease
    Soursou, Georgia
    Alexiou, Athanasios
    Ashraf, Ghulam Md
    Siyal, Asad Ali
    Mushtaq, Gohar
    Kamal, Mohammad A.
    [J]. CURRENT DRUG METABOLISM, 2015, 16 (08) : 705 - 712
  • [7] Mitochondrial abnormalities in Parkinson's disease and Alzheimer's disease: can mitochondria be targeted therapeutically?
    Macdonald, Ruby
    Barnes, Katy
    Hastings, Christopher
    Mortiboys, Heather
    [J]. BIOCHEMICAL SOCIETY TRANSACTIONS, 2018, 46 : 891 - 909
  • [8] Iron in Alzheimer's disease and Parkinson's disease
    Bush, A.
    [J]. JOURNAL OF NEUROCHEMISTRY, 2015, 134 : 5 - 5
  • [9] Glycation in Parkinson's Disease and Alzheimer's Disease
    Vicente Miranda, Hugo
    El-Agnaf, Omar M. A.
    Outeiro, Tiago Fleming
    [J]. MOVEMENT DISORDERS, 2016, 31 (06) : 782 - 790
  • [10] Biomarkers for Alzheimer's disease and Parkinson's disease
    Growdon, John H.
    Irizarry, Michael C.
    Scherzer, Clemens
    [J]. ADVANCES IN ALZHEIMER'S AND PARKINSON'S DISEASE: INSIGHTS, PROGRESS, AND PERSPECTIVES, 2008, 57 : 169 - 174